Harvard Apparatus Regenerative Technology, Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Harvard Apparatus Regenerative Technology, Inc. filed its Q1 2024 10-Q report on May 13, 2024.</b>

AI Summary

Harvard Apparatus Regenerative Technology, Inc. (HRGN) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. The filing is a 10-Q for Harvard Apparatus Regenerative Technology, Inc. for the period ending March 31, 2024. The company's former name was Biostage, Inc. until March 31, 2016. The company's previous former name was Harvard Apparatus Regenerative Technology, Inc. until December 4, 2012. The company is incorporated in Delaware and has a fiscal year end of December 31. The filing includes data related to various stock and capital accounts as of March 31, 2024, and prior periods.

Why It Matters

For investors and stakeholders tracking Harvard Apparatus Regenerative Technology, Inc., this filing contains several important signals. This 10-Q filing provides a quarterly update on the company's financial performance and operational status, crucial for investors to assess recent developments. Understanding the company's historical name changes (Biostage, Inc. and Harvard Apparatus Regenerative Technology, Inc.) is important for tracking its evolution and potential strategic shifts.

Risk Assessment

Risk Level: low — Harvard Apparatus Regenerative Technology, Inc. shows low risk based on this filing. The filing is a standard 10-Q, which is a routine quarterly report and does not contain significant new risks or material adverse events beyond typical business operations.

Analyst Insight

Review the detailed financial statements and disclosures within the 10-Q to understand Harvard Apparatus Regenerative Technology's current financial health and operational performance.

Key Numbers

• 2024-03-31 — Report Period End Date (Conformed period of report)
• 2024-05-13 — Filing Date (Date of filing)
• 2024-01-01 — Quarter Start Date (First day of the reporting quarter)
• 2023-12-31 — Previous Fiscal Year End (Fiscal year end date)

Key Players & Entities

• Harvard Apparatus Regenerative Technology, Inc. (company) — Filer name
• Biostage, Inc. (company) — Former company name
• Harvard Apparatus Regenerative Technology, Inc. (company) — Former company name
• DE (jurisdiction) — State of incorporation
• MA (jurisdiction) — State of business address
• HRGN (ticker) — Ticker symbol

FAQ

Industry Context

The company operates in the surgical and medical instruments & apparatus industry, focusing on regenerative technology.

Regulatory Implications

The filing is a standard 10-Q, subject to SEC regulations for quarterly reporting by public companies.

What Investors Should Do

1. Analyze the balance sheet and income statement for the quarter ended March 31, 2024.
2. Review any disclosures related to changes in accounting policies or significant business events.
3. Compare the current quarter's financial data with historical periods presented in the filing.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q filing.
• 2024-05-13: Filing Date — Date the 10-Q was officially filed with the SEC.

Year-Over-Year Comparison

This is the first 10-Q filing for the fiscal year 2024, providing an update from the previous 10-K filing.

Key Financial Figures

• $0.01 — 5,091 shares of common stock, par value $0.01 per share, outstanding. Harvard Appar

Filing Documents

• form10-q.htm (10-Q) — 570KB
• ex31-1.htm (EX-31.1) — 11KB
• ex31-2.htm (EX-31.2) — 11KB
• ex32-1.htm (EX-32.1) — 6KB
• ex32-2.htm (EX-32.2) — 6KB
• 0001493152-24-018874.txt (&nbsp;) — 3776KB
• hrgn-20240331.xsd (EX-101.SCH) — 30KB
• hrgn-20240331_cal.xml (EX-101.CAL) — 48KB
• hrgn-20240331_def.xml (EX-101.DEF) — 113KB
• hrgn-20240331_lab.xml (EX-101.LAB) — 310KB
• hrgn-20240331_pre.xml (EX-101.PRE) — 244KB
• form10-q_htm.xml (XML) — 396KB

SIGNATURES

SIGNATURES 24 2 PART I. FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements. HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and par value data) March 31, December 31, 2024 2023 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 272 $ 432 Accounts receivable 7 4 Inventory 44 50 Prepaid research and development 159 210 Prepaid expenses and other current assets 135 87 Total current assets 617 783 Property, plant and equipment, net 19 25 Right-of-use assets, net 21 48 Deferred financing costs 544 544 Long-term prepaid contracts 1,214 1,214 Total assets $ 2,415 $ 2,614 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 890 $ 445 Accrued and other current liabilities 528 475 Advance from private placement 301 — Convertible debt – related party 500 — Operating lease liability 21 48 Total current liabilities 2,240 968 Commitments and contingencies (Note 7) - - Stockholders' equity: Common stock, par value $ 0.01 per share, 60,000,000 shares authorized; 13,947,324 issued and outstanding at March 31, 2024 and December 31, 2023, respectively 139 139 Additional paid-in capital 94,023 93,463 Accumulated deficit ( 93,986 ) ( 91,956 ) Accumulated other comprehensive loss ( 1 ) — Total stockholders' equity 175 1,646 Total liabilities and stockholders' equity $ 2,415 $ 2,614 See accompanying notes to unaudited condensed consolidated financial statements. 3 HARVARD APPARATUS REGENERATIVE TECHNOLOGY, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (in thousands, except share and per share data) Three Months Ended March 31, 2024 2023 Product revenue $ 57 $ — Operating expenses: Cost of sales 12 — Research and development 840 509

View Full Filing

View this 10-Q filing on SEC EDGAR